BESREMI

Peak

ropeginterferon alfa-2b

BLASUBCUTANEOUSINJECTABLE
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

interferons, which exhibit their cellular effects in polycythemia vera in the bone marrow by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR). Binding to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular Janus kinase 1 (JAK1)…

Pharmacologic Class:

Interferon alfa-2b

Clinical Trials (4)

NCT04638439Phase 1Completed

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Started Aug 2022
NCT04285086Phase 3Active Not Recruiting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Started Aug 2020
NCT03546465Phase 1Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Started May 2018
NCT04382937Phase 3Completed

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Started Jan 2016